Huadong Medicine Co (SZSE:000963) Long-Term Debt : ¥519 Mil (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Huadong Medicine Co Long-Term Debt?

Huadong Medicine Co's Long-Term Debt for the quarter that ended in Mar. 2024 was ¥519 Mil.

Huadong Medicine Co's quarterly Long-Term Debt declined from Sep. 2023 (¥729 Mil) to Dec. 2023 (¥521 Mil) and declined from Dec. 2023 (¥521 Mil) to Mar. 2024 (¥519 Mil).

Huadong Medicine Co's annual Long-Term Debt increased from Dec. 2021 (¥139 Mil) to Dec. 2022 (¥1,051 Mil) but then declined from Dec. 2022 (¥1,051 Mil) to Dec. 2023 (¥521 Mil).

Huadong Medicine Co Long-Term Debt Historical Data

The historical data trend for Huadong Medicine Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huadong Medicine Co Long-Term Debt Chart

Huadong Medicine Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

151.61

139.18

1,051.46

520.76

Huadong Medicine Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															677.60	746.92	728.51	520.76	519.38

Huadong Medicine Co (SZSE:000963) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Huadong Medicine Co Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Huadong Medicine Co's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Huadong Medicine Co (SZSE:000963) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huadong Medicine Co Ltd (SZSE:000963) » Definitions » Long-Term Debt

Traded in Other Exchanges

N/A

Address

468 Yan’an Road, Floor 7, 9 and 10, Gate No. 1, Building No. 1, Hangzhou, CHN, 310006

Website

http://www.eastchinapharm.com

Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.

Executives

He Ru Fen	Supervisors
Hu Bao Zhen	Supervisors
Zhou Shun Hua	Executives
Shao Ling Min	Supervisors
Wan Ling Ling	Executives
Fu Hang	Director
Yue Jin	Director
Chen Bo	Secretary Dong
Qin Yun	Supervisors
Li Bang Liang	Directors, executives
Zhou Jin Bao	Directors, executives

Huadong Medicine Co (SZSE:000963) Headlines

No Headlines